Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Stock Price Movements and Program Launches Reported by Healthcare Companies - Research Report on Merck, Abiomed, Alere, Raptor



Stock Price Movements and Program Launches Reported by Healthcare Companies -
  Research Report on Merck, Abiomed, Alere, Raptor Pharmaceuticals and West
                           Pharmaceutical Services

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, November 26, 2013

NEW YORK, November 26, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Merck &
Co. Inc. (NYSE: MRK), Abiomed Inc. (NASDAQ: ABMD), Alere Inc. (NYSE: ALR),
Raptor Pharmaceuticals Corp. (NASDAQ: RPTP), and West Pharmaceutical Services,
Inc. (NYSE: WST). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Merck & Co. Inc. Research Report

On November 19, 2013, Merck & Co. Inc. (Merck) announced that its initiative,
Merck for Mothers, has launched programs which are aimed at reducing the
number of women across the US who die from and suffer severe complications
related to pregnancy and childbirth. The Company stated that Merck for
Mothers, which is already working in over 20 countries including Brazil,
India, Senegal, Uganda and Zambia, is now working in the US to address the
following areas: to enhance community initiatives so mothers have access to
services that encourage good health during and beyond pregnancy; to implement
standard approaches addressing obstetric emergencies; and to strengthen data
collection and reviews to improve practices and patient care. Kenneth C.
Frazier, Chairman and CEO of Merck stated, "The rate of maternal mortality is
increasing here in the United States. The tragedy is that many of these deaths
are actually preventable. Merck is working with partners around the globe to
help improve the situation everywhere, including in the United States, to
create a world where no woman dies while giving life." The Full Research
Report on Merck & Co. Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/430d_MRK

--

Abiomed Inc. Research Report

On November 21, 2013, Abiomed Inc.'s (Abiomed) stock closed at $28.37,
reflecting a 4.03% increase. The Company' stock was up by 5.11% over the past
three trading days, compared to the Dow Jones Industrial Average which went up
by 0.21% during the same trading period. The Full Research Report on Abiomed
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/ea34_ABMD

--

Alere Inc. Research Report

On November 21, 2013, Alere Inc.'s (Alere) stock went up by 0.80% closing at
$32.89 per share. The Company's stock was down 1.26% over the previous three
trading sessions, compared to the S&P 500, which was up by 0.24% during the
same trading period. The Full Research Report on Alere Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/5da1_ALR

--

Raptor Pharmaceuticals Corp. Research Report

On November 21, 2013, Raptor Pharmaceuticals Corp.'s (Raptor Pharmaceuticals)
stock was up by 7.83%, closing at $13.22. Over the past three trading
sessions, the Company's stock was up by 9.98%, compared to the Nasdaq
Composite, which went up by 0.51% during the same trading period. The Full
Research Report on Raptor Pharmaceuticals Corp. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/a001_RPTP

--

West Pharmaceutical Services, Inc. Research Report

On November 21, 2013, West Pharmaceutical Services, Inc.'s (West
Pharmaceutical Services) stock was up by 3.13% closing the day at $48.80. The
Company's stock went up by 3.11% over the past three trading sessions,
compared to the Dow Jones Industrial Average, which went up by 0.21% during
the same trading period. The Full Research Report on West Pharmaceutical
Services, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/39a2_WST

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement